Nautilus Biotechnolgy (NAUT) AI Stock Analysis

• Market Cap: $256.40M
• Dividend Yield: N/A
• Average Volume (3M): 394.63K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.64
• Revenue Growth: N/A
• EPS Growth: 11.15%
• Country: US
• Employees: 134
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.11
• Shares Outstanding: 126,305,120
• 10 Day Avg. Volume: 378,207
• 30 Day Avg. Volume: 394,629
• PEG Ratio: -0.30
• Price to Book (P/B): 1.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.44
• Enterprise Value/Market Cap: 1.11
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -25.36
• Enterprise Value/Ebitda: -5.52
• 1Y Price Target: $2.50
• Price Target Upside: 23.15% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: $2.50 ▲(23.15% Upside)

The score is held back primarily by pre-revenue status, persistent sizable losses, and ongoing cash burn that imply continued financing/dilution risk. Offsetting factors include modest leverage and a positive earnings-call outlook on cost discipline, cash runway, and progress toward commercialization, while technicals appear neutral-to-slightly positive and valuation remains difficult to justify with negative earnings.

Positive Factors

Platform scientific progress

Publication of the iterative mapping method and demonstrated platform progress signal durable technical differentiation. A validated, instrument-centric proteomics approach strengthens barriers to entry, supports consumables and software ecosystems, and underpins sustainable adoption by research and pharma customers.

High-quality strategic partnerships

Partnerships with respected research institutes (Buck, Allen, Mount Sinai) accelerate validation, create proprietary datasets, and lend credibility to the technology. These collaborations help de-risk product development and build long-term customer relationships that support commercial traction.

Cost discipline and multi-year cash runway

Operating expenses cut 19% YoY and a reported cash position (ended quarter with $168.5M) yielding runway through 2027 provide durable financing visibility. This allows focus on commercialization milestones and reduces immediate dilution risk while pursuing product launch timelines.

Negative Factors

Pre-revenue business model

Being pre-revenue means no recurring sales to offset R&D and OPEX. Sustained development-stage spending with no incoming product revenue places execution risk front-and-center: prolonged commercialization timelines or weak adoption could materially impair long-term viability.

Consistent negative cash generation

Persistent negative operating and free cash flow indicates ongoing funding needs. While losses are largely cash-backed, continued negative cash generation requires future financing or revenue ramps; failure to achieve commercial revenue would force dilution or strategic compromises.

Balance sheet erosion and dilution risk

Material decline in equity over several years and strongly negative ROE reflect cumulative losses and prior financing. Although leverage is modest, the weakened equity base increases the likelihood of future dilution if commercial milestones or revenue ramps are delayed, pressuring long-term shareholder value.

Nautilus Biotechnolgy Business Overview & Revenue Model

Company Description

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

How the Company Makes Money

Nautilus Biotechnology generates revenue primarily through the commercialization of its proteomics platform. The company offers its technology to pharmaceutical companies, academic institutions, and research organizations, which use it to conduct detailed protein analysis. Key revenue streams include the sale of instruments, consumables, and related services required to operate the platform. Additionally, Nautilus may engage in strategic partnerships and collaborations with other entities in the biotech and pharmaceutical industries, which can provide further revenue through joint research projects, licensing agreements, and milestone payments based on the successful achievement of specific research or development goals.

Nautilus Biotechnolgy Financial Statement Overview

Summary

Weak fundamentals driven by $0 revenue, sustained large losses (TTM net loss ~$62.8M; EBIT ~$71.4M), and heavy ongoing cash burn (TTM FCF ~$53.9M negative). Balance sheet leverage is modest (debt-to-equity ~0.16), but equity has declined materially since 2021, implying continued dilution/financing risk.

Income Statement

The company remains pre-revenue (revenue is $0 across all periods provided), with persistent and sizable losses. TTM (Trailing-Twelve-Months) net loss is about -$62.8M and EBIT is about -$71.4M, reflecting ongoing operating burn rather than improving profitability. Losses have stayed elevated over time (annual net losses roughly in the -$50M to -$71M range since 2021), with no clear path to near-term margin stabilization based on the data shown.

Balance Sheet

Leverage is modest for a development-stage biotech: TTM (Trailing-Twelve-Months) debt is ~$27.0M versus equity of ~$169.1M (debt-to-equity ~0.16). However, the balance sheet has weakened over time as equity has declined materially (from ~$363.6M in 2021 to ~$169.1M TTM), consistent with sustained losses. Returns on equity are strongly negative in recent periods (TTM roughly -33%), highlighting ongoing value dilution risk if losses persist.

Cash Flow

Cash generation is consistently negative, with TTM (Trailing-Twelve-Months) operating cash flow of about -$52.6M and free cash flow of about -$53.9M. Free cash flow trends are volatile and negative (TTM free cash flow growth is sharply lower), indicating continuing funding needs. A relative positive is that free cash flow is broadly in line with net loss (TTM free cash flow to net income ~1.02), suggesting losses are largely cash-backed rather than heavily boosted by non-cash accounting items.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-11.23M	-6.35M	-5.71M	-3.42M	-2.84M	-2.35M
EBITDA	-51.58M	-64.43M	-74.30M	-54.51M	-47.47M	-13.27M
Net Income	-62.81M	-70.78M	-63.67M	-57.92M	-50.31M	-15.62M
Balance Sheet
Total Assets	200.91M	242.74M	305.56M	350.05M	398.45M	85.01M
Cash, Cash Equivalents and Short-Term Investments	131.43M	129.89M	173.42M	184.47M	345.73M	76.74M
Total Debt	27.00M	30.48M	34.63M	30.33M	30.03M	4.78M
Total Liabilities	31.78M	34.01M	40.21M	35.13M	34.87M	114.73M
Stockholders Equity	169.14M	208.73M	265.35M	314.92M	363.58M	-29.72M
Cash Flow
Free Cash Flow	-53.92M	-61.27M	-54.15M	-48.13M	-41.51M	-14.92M
Operating Cash Flow	-52.63M	-59.15M	-51.71M	-45.81M	-39.24M	-14.00M
Investing Cash Flow	71.54M	66.25M	-43.73M	-25.74M	-138.96M	-25.28M
Financing Cash Flow	553.00K	1.14M	368.00K	562.00K	327.45M	75.90M

Nautilus Biotechnolgy Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.03
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NAUT, the sentiment is Positive. The current price of 2.03 is above the 20-day moving average (MA) of 2.03, above the 50-day MA of 2.03, and above the 200-day MA of 1.14, indicating a bullish trend. The MACD of 0.05 indicates Negative momentum. The RSI at 58.48 is Neutral, neither overbought nor oversold. The STOCH value of 65.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NAUT.

Nautilus Biotechnolgy Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KLRS	60 Neutral	$164.87M	-1.30	-63.45%	―	―	63.31%
ABOS	54 Neutral	$125.99M	-1.23	-85.93%	―	―	-60.99%
SEER	54 Neutral	$108.23M	-1.40	-25.74%	―	13.77%	-4.76%
NAUT	52 Neutral	$256.40M	-4.48	-32.00%	―	―	11.15%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VTGN	46 Neutral	$24.66M	-0.38	―	―	-33.00%	54.91%

Nautilus Biotechnolgy Corporate Events

Nautilus Biotechnology Regains Nasdaq Compliance

On November 3, 2025, Nautilus Biotechnology, Inc. announced that it has regained compliance with Nasdaq’s Listing Rule 5550(a)(2), ensuring its continued listing on The Nasdaq Capital Market. This follows a previous notice in May 2025, when the company failed to meet the minimum bid price requirement. After transferring to The Nasdaq Capital Market in October 2025, Nautilus Biotechnology successfully met the compliance requirements, closing the matter.

The most recent analyst rating on (NAUT) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Nautilus Biotechnolgy stock, see the NAUT Stock Forecast page.